Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advancing Vision Research LLC

Neither a doctor nor a teaching hospital

Research payments

$760,070

256 payments

Through program year 2025, Advancing Vision Research LLC is reported as receiving $760,070 in research payments, across 256 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $91,356 18
2024 Research $81,514 19
2023 Research $47,056 15
2022 Research $242,979 60
2021 Research $202,108 56
2020 Research $63,150 81
2019 Research $31,908 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $266,567 50 payments
  2. Alcon Research LLC $213,456 186 payments
  3. Novartis Pharmaceuticals Corporation $178,230 5 payments
  4. Aerie Pharmaceuticals, Inc. $66,800 8 payments
  5. Allergan Inc. $21,345 3 payments
  6. Mallinckrodt Hospital Products Inc. $7,360 2 payments
  7. Osmotica Pharmaceutical Corp. $6,313 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Placebo-Controlled, Double-Masked, Multi-Center, Dose-Ranging Study to Evaluate the Safety, and Efficacy of Unr844 in Subjects With Presbyopia $99,022 2 payments
  2. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $71,157 16 payments
  3. A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects with Presbyopia $63,939 3 payments
  4. A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease $59,575 6 payments
  5. Mercury Extended Wear Registration Trial(Weekly SiHy NW Sphere (Mercury)) $57,024 80 payments
  6. Clinical Assessment of Two Reusable Silicone Hydrogel Contact Lenses $54,504 78 payments
  7. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced $50,829 1 payment
  8. A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $49,280 2 payments
  9. AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $40,855 16 payments
  10. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (PRK) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries $25,363 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record